Learn
A little clarity for your next decision.
Loading your learning library…
Investor WorkspaceWelcome, there!Log Out
Investor WorkspaceA little clarity for your next decision.
By Jerry Baker
Life science REITs own laboratories and related buildings used for research, testing, and product development. Their rental income depends on tenants that can fund their work and space that remains useful to the next user. This guide explains how to review tenant funding, lab costs, lease terms, and local supply before judging the investment.
Buying shares in a life science REIT is not the same as buying a drug developer. The landlord may collect rent whether a tenant's research succeeds or fails. But that separation has limits: a tenant that runs out of money may stop paying rent, reduce space, or seek changes to its lease.
I would start with the rent roll, not a list of promising therapies. Find out which legal entities owe rent, how much each pays, and what supports those payments. A well-known researcher or an exciting product does not replace that work.
The buildings also vary. Some contain wet labs where researchers work with chemicals or biological materials. Others combine offices, computing space, testing areas, and pilot facilities. Research space and commercial manufacturing space may have different systems, permits, and user needs.
Ask what is already in place and what the owner has promised to build. An empty shell with future plans is a different investment from a completed lab earning rent. A signed lease is another step, but it may still require costly work before the tenant moves in.
The FDA describes drug development as a process involving discovery, preclinical work, clinical research, review, and safety monitoring after approval. Moving through one stage does not eliminate the need for later work or establish that a product will be approved. [1]
As a real estate investor, I do not need to pretend I can predict every trial outcome. I do need to understand whether the tenant's finances depend on one event. A company with several marketed products may have a different cash profile from a startup funding its first study.
Make a short list of the tenant's next major dates. When does it expect trial results? When does it need more money? When does a large partner payment become due? When does its lease require rent increases or more space?
Those dates may overlap. If the next funding round depends on favorable results, and the results arrive shortly before cash runs low, the landlord faces a narrow margin for delay. A ten-year lease does not create ten years of cash in the tenant's account.
Also ask whether the tenant's parent stands behind the lease. A subsidiary may use a large company's name without receiving an unlimited guarantee. Read the actual contract rather than relying on the logo.
Cash runway is a rough estimate of how long money may last at a given rate of spending. It is a useful starting point, but spending rarely follows a perfectly flat line.
Consider an original hypothetical tenant with $120 million of usable cash. It spends $8 million more than it receives each month. Dividing cash by that monthly shortfall gives 15 months of runway. If monthly use rises to $10 million during a trial, the same cash supports only 12 months.
Suppose rent is $2 million a year. It would be a mistake to divide $120 million by rent and conclude that the tenant has 60 years of rent coverage. The company also has payroll, research, vendors, debt, and other commitments. Rent competes with those uses of cash.
Read restrictions on cash, committed payments, and debt terms. Then ask what is already funded versus merely expected. A planned financing round, unsigned partnership, or potential asset sale is not cash available today.
I would also test a delayed milestone. If a key event shifts six months, what costs continue during the wait? Does the tenant have room to cut spending without destroying the program on which future funding depends?
Research tenants may receive grants, equity funding, product revenue, contract payments, or support from a parent. Each has different conditions. A grant awarded for one project is not automatically a general-purpose reserve for every bill.
NIH states that its awards are subject to the Notice of Award, grant authorities, applicable laws, and other terms. For a tenant supported by grants, review the actual award and permitted uses instead of assuming all announced funding is unrestricted cash. [2]
Partnership announcements also need context. A headline may include a small payment now and much larger payments tied to future events. The maximum possible deal value may have little resemblance to money that can pay next month's rent.
Build separate columns for cash received, committed future payments, and conditional payments. Put the expected date and remaining condition next to each amount. This makes the credit discussion much clearer than adding every headline number together.
A university connection can be valuable for talent and research. It does not, by itself, make the university responsible for a separate company's rent. Identify the tenant, payer, and guarantor in writing.
A lab can require ventilation, protective equipment, reliable power, plumbing, and other systems suited to its actual work. Those features may make a building attractive to a particular user. They can also create higher maintenance costs and limit the pool of future users.
OSHA's laboratory standard applies to covered employers using hazardous chemicals in laboratory work. It requires a written chemical hygiene plan and measures to keep fume hoods and other protective equipment working properly. Its scope and exceptions matter; it is not one universal operating rule for every kind of research or manufacturing facility. [3]
For the property review, ask an engineer which systems belong to the landlord and which belong to the tenant. Check condition, capacity, inspection records, and planned replacement dates. The lease should help explain who pays, but it cannot substitute for a physical assessment.
Imagine a ventilation upgrade costing $2 million. If the next tenant needs it before moving in, the owner may have to fund that work long before rent starts. If the tenant's process needs a different system, part of the existing investment may offer little value.
Higher replacement cost does not establish market value. An expensive feature can be useful, obsolete, or simply unnecessary for the next user. I want to know what tenants will pay for the building as it exists today.
Alexandria's second-quarter 2026 supplemental report shows why precise definitions matter. It reported 86.9% occupancy for operating properties, excluding assets held for sale, at June 30. Including executed leases with future occupancy raised that measure to 90.9%. Its operating-and-redevelopment measure was lower. These are different groups and stages of leasing. [4]
The same report showed an 8.6% decline in second-quarter same-property net operating income on a cash basis. That was a company result for a stated quarter, not a forecast for every lab owner. It also was not the same measure as the six-month result or shareholder cash flow. [4]
Those distinctions matter more than picking the most attractive number. Ask whether a leasing figure includes negotiations, signed leases, completed space, or paying tenants. A plan under discussion should not appear in the same column as rent already being collected.
Check what leaves a comparison group. Sales, redevelopment, and changes in property status may change the denominator. An occupancy increase caused by selling vacant buildings tells a different story from filling those buildings with tenants.
A local lab market can have several sources of competing space: empty existing buildings, new construction, planned projects, and space offered by tenants through subleases. Each should be tracked separately.
A tenant with unused space may offer a discount to reduce its own cost. That can compete with a landlord's vacant suite even when no new building opens. At the same time, a short sublease may not suit a tenant planning a large, long-term research program.
For a hypothetical market, assume 5 million square feet of existing lab space, including 500,000 vacant square feet. Another 500,000 is under construction. If none of the new space is occupied and existing use does not change, vacancy becomes 1 million square feet out of 5.5 million, or about 18.2%.
The starting vacancy was 10%. Adding new space equal to 10% of the old inventory did not produce 20% vacancy because the denominator changed too. This example ignores preleasing, conversions, demolitions, and tenant moves. A real study needs those details.
Ask which projects will actually compete with the portfolio. Different lab types, locations, suite sizes, and delivery dates may serve different users. A citywide total can hide a shortage in one niche and a surplus in another.
A quoted rent is only one part of the agreement. Free rent, tenant improvement allowances, commissions, operating expenses, and restoration duties can change the result.
Here is an original example. A 20,000-square-foot suite rents for $70 per square foot a year for five years, with no scheduled increases. Face rent totals $7 million. Assume one year of free base rent, $2 million of landlord-funded improvements, and $200,000 of commissions.
Subtracting those three items leaves $3.4 million over five years, before other expenses and the time value of money. Spread evenly, that is $34 per square foot per year. It is a simple cash comparison, not an accounting rent measure or a complete investment return.
Now compare another lease with lower face rent but less free rent and smaller improvements. It may provide better cash results. Use the same period and cost assumptions for both.
Also separate work needed to keep the building usable from work that expands it. A report may label some spending as growth investment, but the investor still needs to know how much cash must leave the business before rent can continue.
Specialized space can be hard to move out of. That may encourage a tenant to renew. It can also be hard to lease again after the tenant leaves. Both can be true at once.
Ask for a reuse plan. Can the suite serve another lab user with modest changes? Can it be split? Must equipment be removed? Who handles decontamination and verifies that the space is ready for the next use?
Environmental review belongs here as well. EPA explains that property ownership can carry liability under CERCLA, while certain defenses require pre-acquisition inquiry and other conditions. A prior environmental report or tenant promise is not a blanket shield against all liability. [5]
Build a timeline that includes permits, design, work, testing, and tenant approvals. A six-month construction estimate is not necessarily a six-month period without rent. It may follow several months spent finding the tenant and agreeing on plans.
If a suite normally produces $100,000 in monthly base rent, nine months without rent means $900,000 of foregone receipts. Add $600,000 of work and leasing costs, and the impact is $1.5 million before carrying costs. That amount should be tested against the property's reserves and debt obligations.
Being near research institutions, workers, suppliers, and other companies can help a lab tenant. But several buildings in one research hub may face the same funding cycle and competing supply.
Count exposure by location, tenant parent, and funding source. Ten small tenants are not fully independent risks if all need a new financing round in the same year. Two different building names may belong to the same parent company.
FINRA's guidance on concentration risk emphasizes looking across investments rather than relying only on the number of holdings. For this sector, I would apply that idea to both the REIT's properties and the rest of your portfolio. [6]
If you already own biotechnology stocks, work for a research company, and hold a lab-focused REIT, several parts of your finances may react to the same conditions. The real estate label does not automatically remove that overlap.
Set a limit based on what a setback would mean for you. Do not choose an allocation solely because the scientific story is exciting.
A development plan should distinguish land, projects under construction, signed preleases, and completed income-producing space. Planned rent may be years away, while interest, taxes, and construction bills arrive sooner.
Assume a hypothetical project costs $50 million and is expected to produce $3.5 million of annual property income once stabilized. That is a 7% income-to-cost ratio. If cost rises to $60 million and expected income falls to $3 million, the ratio becomes 5%.
Neither number is a shareholder return. They exclude financing, corporate expenses, the timing of cash, and the eventual sale. They simply show how changes in cost and rent can alter a project.
Ask about the ability to pause or change plans. A halted project may reduce future spending but leave money tied up in land and unfinished work. Converting a planned lab to another use may require new permits and a revised budget.
Compare construction commitments with available funding. Expected proceeds from a future property sale are not as certain as cash already received. A financing plan that depends on several favorable events deserves a downside case.
Debt maturities can force decisions before the real estate market improves. Banking guidance on refinancing risk addresses the chance that maturing debt cannot be replaced on acceptable terms. A REIT's timing problem may be as important as its long-term leasing thesis. [7]
For example, replacing $30 million of debt carrying 4% interest with the same balance at 7% adds $900,000 of annual interest. If annual property income is $3 million, that increase equals 30% of that income before other claims. A required principal paydown would be another use of cash.
Read funds from operations, or FFO, with its reconciliation. FFO is a supplemental performance measure, not the amount a shareholder can spend. Capital work, lease costs, debt payments, and other needs require separate attention. [8]
Look at results per share. If the company issues more shares to fund projects, total income may rise without an equal benefit for each existing share. Also separate gains from investments in tenant companies from recurring rent. A venture investment and a lease have different risks.
A cash deposit, letter of credit, or guarantee may reduce part of a loss. Read how much protection remains, when it expires, and what the owner must do to claim it. A letter of credit that expires before a tenant's next funding event may leave a gap at the wrong time.
Also ask whether the protection declines as the lease ages. Do not compare the original security amount with today's risk if the contract has already reduced it. Counsel should review enforceability and claim conditions; the investment model should use the protection actually available.
I would build a short file with three parts. First, explain the tenant cash story: who pays rent, where their funds come from, and what happens if the next milestone is late. Second, explain the building: what makes it useful, what it costs to maintain, and who could use it next. Third, explain the owner: debt, cash, commitments, and results per share.
Include a case with lower rent, longer downtime, and higher work costs. State how the REIT would fund that case. If the answer requires selling assets, show a lower sale price too.
Finally, review the security's terms. Listed REIT shares can trade quickly but at a loss. Nontraded or private shares may be difficult to sell, and repurchase programs have conditions. Dividends and capital values are not guaranteed. [9]
Ordinary REIT shares are not qualifying replacement real property in a Section 1031 exchange. The company may own laboratories, but a shareholder owns a security. Do not substitute the building's asset type for the tax treatment of the interest you buy. [10]
Its main exposure may be real estate leased to research companies, rather than direct ownership of their products. Still, tenant success and funding can affect rent. Some REITs also make separate venture investments, which should be reviewed on their own.
No. A building's systems only support rent when tenants need them and can pay. Specialized features may also make the space harder to reuse. Compare actual leasing demand with the cost of maintenance, upgrades, and future tenant work.
It is a rough estimate of how long a tenant's cash may last at an assumed spending rate. Review restrictions and future costs before relying on it. Expected financing or a possible milestone payment should not be counted as money already in the bank.
No. A lease may be signed before improvements are complete and before occupancy or rent begins. Read each issuer's definitions and timing. Separate negotiations, signed commitments, physical use, and cash rent rather than combining them into one number.
A tenant may depend on grant funding for its work. Awards have conditions and permitted uses, so an announced award does not automatically support every lease obligation. Review the actual award and the tenant's broader finances. [2]
Sometimes, but feasibility depends on design, permits, local demand, work costs, and the economics of the new use. A conversion plan needs evidence and a budget. It should not be treated as an automatic fallback value.
Ordinary REIT shares do not qualify as replacement real property. Any separate transaction proposed for an exchange requires its own legal and tax review. Owning real estate through a corporation does not make its shares direct real estate. [10]
Educational information, not an offer or a personal tax, legal, or investment recommendation. Examples are hypothetical and omit stated adjustments. Tax treatment depends on your facts and current law. Review your transaction with your CPA, attorney, and qualified intermediary. Real estate investments can lose value and may be illiquid.
Enter your approved email to explore investments, save your shortlist, and keep learning.